Maybe we are getting a little snarky but after covering this wacky world of ours for more than 20 years we still cannot believe the things companies do. Yesterday we noted that Lilly (NYSE: LLY) seems somewhat clueless as to the devasting impact Amedlog will have on sales of Humalog, a $3 billion product. But then again Sanofi (NYSE: SNY) was also clueless before Basaglar hit the market. The question that circles around in our mind is why? How can these people not see or grasp the realities of the market?
We keep asking why Lilly wants to be in . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.